Largest pharmaceutical companies in the United States by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Pfizer leads the 44 pharmaceutical companies in the United States ranked by net assets, at SAR 324.4B, ahead of Johnson & Johnson (SAR 305.9B) and Merck & Co (SAR 197.4B). Figures as of 20 Nov 2026, 05:37 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 44
- First
- PfizerSAR 324.4B
- Median
- SAR 2.5B
- Combined market value
- SAR 14.02T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | PfizerPFE · Health Care | SAR 324.4B | SAR 588.9B | SAR 103.32 | 1.85% down | 15% up | ||
| 2 | Johnson & JohnsonJNJ · Health Care | SAR 305.9B | SAR 2.41T | SAR 1,002.18 | 2.04% down | 34% up | ||
| 3 | Merck & CoMRK · Health Care | SAR 197.4B | SAR 1.23T | SAR 498.24 | 3.61% down | 45% up | ||
| 4 | Abbott LaboratoriesABT · Health Care | SAR 195.6B | SAR 674.9B | SAR 389.67 | 0.58% down | 16% down | ||
| 5 | Regeneron PharmaceuticalsREGN · Health Care | SAR 117.3B | SAR 358.3B | SAR 3,463.91 | 2.35% down | 28% up | ||
| 6 | Eli LillyLLY · Health Care | SAR 99.5B | SAR 4.51T | SAR 5,068.73 | 2.29% down | 33% up | ||
| 7 | Vertex PharmaceuticalsVRTX · Health Care | SAR 70B | SAR 495.2B | SAR 1,953.26 | 2.94% down | 27% up | ||
| 8 | Bristol-Myers SquibbBMY · Health Care | SAR 69.3B | SAR 447.4B | SAR 218.86 | 2.05% down | 30% up | ||
| 9 | ViatrisVTRS · Health Care | SAR 55.2B | SAR 85.5B | SAR 74.58 | 1.97% down | 99% up | ||
| 10 | Royalty PharmaRPRX · Health Care | SAR 36.4B | SAR 146.1B | SAR 254.05 | 1.38% down | 79% up | ||
| 11 | United TherapeuticsUTHR · Health Care | SAR 26.6B | SAR 89.3B | SAR 2,097.46 | 3.16% down | 22% up | ||
| 12 | Elanco Animal HealthELAN · Health Care | SAR 24.6B | SAR 49.3B | SAR 98.63 | 1.54% down | 26% up | ||
| 13 | BioMarin PharmaceuticalBMRN · Health Care | SAR 22.8B | SAR 44.6B | SAR 230.42 | 0.02% down | 17% up | ||
| 14 | ZoetisZTS · Health Care | SAR 12.5B | SAR 123.1B | SAR 303.08 | 5.59% down | 26% down | ||
| 15 | Ligand PharmaceuticalsLGND · Health Care | SAR 3.8B | SAR 21.5B | SAR 1,076.46 | 3.94% down | 50% up | ||
| 16 | Legend BiotechLEGN · Health Care | SAR 3.8B | SAR 11.7B | SAR 60.40 | 0.92% down | 41% down | ||
| 17 | Praxis Precision MedicinesPRAX · Health Care | SAR 3.3B | SAR 32.6B | SAR 1,166.34 | 1.87% up | 86% up | ||
| 18 | Alnylam PharmaceuticalsALNY · Health Care | SAR 3B | SAR 74.3B | SAR 554.55 | 1.06% down | 66% down | ||
| 19 | Belite BioBLTE · Health Care | SAR 2.9B | SAR 23B | SAR 566.55 | 3.33% down | 43% up | ||
| 20 | InsmedINSM · Health Care | SAR 2.8B | SAR 118.9B | SAR 541.94 | 20.58% up | 40% down | ||
| 21 | Spyre TherapeuticsSYRE · Health Care | SAR 2.7B | SAR 34.8B | SAR 366.26 | 3.77% down | 332% up | ||
| 22 | Summit TherapeuticsSMMT · Health Care | SAR 2.5B | SAR 31.7B | SAR 39.65 | 0.67% up | 36% down | ||
| 23 | TG TherapeuticsTGTX · Health Care | SAR 2.4B | SAR 36.8B | SAR 243.40 | 1.88% down | 117% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | SAR 2.4B | SAR 26.7B | SAR 243.77 | 4.15% down | 10% down | ||
| 25 | Cogent BiosciencesCOGT · Health Care | SAR 2.4B | SAR 18.1B | SAR 104.07 | 0.25% down | 20% down | ||
| 26 | Protagonist TherapeuticsPTGX · Health Care | SAR 2.3B | SAR 30.4B | SAR 465.26 | 2.47% down | 51% up | ||
| 27 | Madrigal PharmaceuticalsMDGL · Health Care | SAR 2.3B | SAR 34.6B | SAR 1,488.37 | 0.34% down | 27% down | ||
| 28 | Edgewise TherapeuticsEWTX · Health Care | SAR 2B | SAR 16.9B | SAR 154.45 | 0.48% down | 86% up | ||
| 29 | Dianthus TherapeuticsDNTH · Health Care | SAR 1.9B | SAR 17.9B | SAR 318.24 | 1.01% up | 108% up | ||
| 30 | Ionis PharmaceuticalsIONS · Health Care | SAR 1.8B | SAR 17B | SAR 102.12 | 0.62% down | 63% down | ||
| 31 | Oruka TherapeuticsORKA · Health Care | SAR 1.8B | SAR 24.8B | SAR 366.03 | 1.91% up | 255% up | ||
| 32 | Arrowhead PharmaceuticalsARWR · Health Care | SAR 1.7B | SAR 23.1B | SAR 163.75 | 1.25% up | 13% up | ||
| 33 | Definium TherapeuticsDFTX · Health Care | SAR 1.2B | SAR 15.1B | SAR 110.59 | 1.24% up | 168% up | ||
| 34 | ErascaERAS · Health Care | SAR 1.2B | SAR 18.7B | SAR 53.35 | 3.34% up | 395% up | ||
| 35 | Mirum PharmaceuticalsMIRM · Health Care | SAR 1.2B | SAR 23.4B | SAR 358.31 | 3.27% up | 34% up | ||
| 36 | Rhythm PharmaceuticalsRYTM · Health Care | SAR 521.7M | SAR 30.4B | SAR 438.18 | 1.88% down | 18% up | ||
| 37 | Travere TherapeuticsTVTX · Health Care | SAR 430.8M | SAR 17.4B | SAR 181.20 | 3.86% down | 45% up | ||
| 38 | Axsome TherapeuticsAXSM · Health Care | SAR 331.2M | SAR 26.8B | SAR 509.00 | 1.25% up | 6% down | ||
| 39 | Amneal PharmaceuticalsAMRX · Health Care | -SAR 265.6M | SAR 28B | SAR 80.24 | 2.24% down | 90% up | ||
| 40 | VeradermicsMANE · Health Care | -SAR 454M | SAR 19.7B | SAR 466.65 | 0.38% down | 231% up | ||
| 41 | PTC TherapeuticsPTCT · Health Care | -SAR 770.2M | SAR 18.3B | SAR 218.81 | 3.16% down | 21% down | ||
| 42 | CytokineticsCYTK · Health Care | -SAR 2.5B | SAR 26.9B | SAR 193.05 | 0.27% up | 19% down | ||
| 43 | BridgeBio PharmaBBIO · Health Care | -SAR 7.8B | SAR 57.1B | SAR 293.29 | 0.22% up | 21% up | ||
| 44 | AbbVieABBV · Health Care | -SAR 12.3B | SAR 1.88T | SAR 1,063.70 | 0.86% down | 25% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7515 SAR).
Questions and answers
Which pharmaceutical companies in the United States rank first by net assets?
Pfizer (SAR 324.4B), Johnson & Johnson (SAR 305.9B) and Merck & Co (SAR 197.4B) are the top three of the 44 pharmaceutical companies in the United States ranked by net assets as of 20 Nov 2026, 05:37 UTC.
How many pharmaceutical companies in the United States are in this ranking?
44 are ranked by net assets.
What are these pharmaceutical companies in the United States worth together?
The 44 pharmaceutical companies in the United States ranked by net assets have a combined market value of SAR 14.02T as of 20 Nov 2026, 05:37 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by net assets”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.